Study: Ivacaftor Improves Lung Function, Reduces Complications in Cystic Fibrosis

Patients with cystic fibrosis (CF) who were treated with ivacaftor

have demonstrated favorable results for clinically important outcomes, including a lower prevalence of CF-related complications and improved lung function, according to a new study.

The study

, published in Thorax

,

assessed the clinical outcomes and disease progression in ivacaftor-treated patients using data from the US and United Kingdom (UK) CF registries. Ivacaftor was described as the first CF transmembrane conductance regulator (CFTR) modulator that demonstrated clinical benefits in patients with CF.

“Ivacaftor is intended for chronic, lifelong use. Therefore, understanding the long-term effects of therapy is important for patients, caregivers, healthcare providers, payers and regulators,” the authors said. “Furthermore, since the therapy addresses the underlying cause of CF, long-term data are complementary to data from the clinical development programs.”

Click to continue reading on The American Journal of Managed Care.